Xellar Biosystems
耀速科技
Xellar Biosystems (耀速科技) is an AI-driven organ-on-chip platform company developing 3D biological intelligence for drug discovery. Per ZhenFund, its platform entered the FDA's Innovation Science and Technology Advancement Program review pathway in January 2026, positioning it among the first drug-development tools globally to pursue formal FDA scientific qualification . The company has published jointly with Pfizer on research outcomes and, as of January 2025, had work featured simultaneously in two Nature sub-journals . ZhenFund backed Xellar at the angel stage and has continued to support it through subsequent rounds, including a new tens-of-millions-yuan financing in April 2025 and a Series A exceeding RMB 200 million that closed by March 2026 .
AI-generated — may contain errors, please verify.
Coverage
When AI Starts Doing Science: A Recap of the SSCI Leading Fund × Dalton Venture Tong Academy Event
Scientific exploration has no end point, and innovation in the age of intelligence has only just begun.
When AMD Acquires Taalas, a Chinese Company Decides to Etch AI Models into Silicon
The era of specialized inference compute has arrived.
Wanwu Capital | Z News
We invite you to revisit the July "highlight reel."
ZhenFund angel project Lxson completes nearly 500 million RMB Pre-A funding round, launches home embodied intelligence brand "Zeroth"
Outstanding orders have surpassed 30,000 units, securing an early foothold at a critical entry point for home embodied intelligence.
ZhenFund angel project "YuanCe Future" (源策未来) has raised hundreds of millions of RMB in its Series A funding round, aiming to build the OpenAI of the humanoid robot era.
A University of Hong Kong professor has founded a startup to build a general-purpose, full-body embodied intelligence brain.
ZhenFund Celebrates Another Angel-Stage IPO in Three Weeks as "UISEE" — the First Full-Scenario L4 Autonomous Driving Stock — Lists on Hong Kong Stock Exchange
Accelerate the large-scale adoption and application of AI drivers.
ZhenFund Angel Portfolio Company "Xellaris" Closes Over RMB 200 Million Series A Round, Defining a New Paradigm for AI Drug Discovery with 3D Biological Intelligence
To bring more breakthrough therapies to patients worldwide.
Beyond the Cliff, Grass Yet Untrodden | Z News
We stand ready to receive, in the depths of our being, those miracles that arrive unforeseen.
ZhenFund angel project "Lexiang Technology" announces completion of angel+ round, bringing total angel-round financing to nearly RMB 300 million | Z News
The proceeds from this round will go primarily toward team building and the mass production and development of the product platform.
ZhenFund angel project "Weiming Shiguang" announces completion of strategic funding round of nearly 100 million RMB | Z News
The proceeds from this round will be used to accelerate the advancement of its diversification and globalization strategy.
ZhenFund angel project "Yaosu Technology" announces completion of new tens of millions of yuan funding round | Z News
The proceeds from this round will be used to accelerate the construction of its organ chip, wet lab, and AI algorithm "3D-Wet-AI" closed-loop system, and to further expand international partnerships and multi-scenario commercial deployment.
A New Year Dawns, Auspicious Energy Fills the Door｜Z News
Welcoming the Year of the Snake, embarking on a new journey.
First Snow, Clear Skies After Frost — Good News as Autumn Departs | Z News
The early winter breeze is crisp and clear.
Summer rains bring gentle relief, good things flourish like green grass | Z News
Long, languid July.
